Clinical Trials
86 trialsA Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Institutes of Health Clinical Center (CC)
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen Inc.
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
DS-3201b in Participants With Lymphomas
Daiichi Sankyo
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
CABAL2
Baylor College of Medicine
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Canadian Cancer Trials Group
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Taiho Oncology, Inc.
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Seagen Inc.
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Henan Cancer Hospital
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Treeline Biosciences, Inc.
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co., Ltd
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
Boston Immune Technologies and Therapeutics
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
COURAGE
Tianjin Medical University Cancer Institute and Hospital
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Kymera Therapeutics, Inc.
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings, Inc.
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
Institute of Hematology & Blood Diseases Hospital, China
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Taiho Oncology, Inc.
Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
Axter Therapeutics (Beijing) Co., Ltd
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
Innate Pharma
Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Wake Forest University Health Sciences
Ipilimumab and Local Radiation for Selected Solid Tumors
Stanford University
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Stanford University
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
University of Nebraska
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Henan Cancer Hospital
CERTAIN
Tessa Therapeutics
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Karyopharm Therapeutics Inc
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
National Institutes of Health Clinical Center (CC)
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
EpiBrentlen
Peter MacCallum Cancer Centre, Australia
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institutes of Health Clinical Center (CC)
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
TG Therapeutics, Inc.
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Acrotech Biopharma Inc.
Phase 1b Safety and Efficacy Study of TRU-016
Aptevo Therapeutics